New cocktail of immunotherapy, targeted drug, chemo, and radiation takes on lung cancer
NCT ID NCT07538258
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemotherapy (cisplatin or carboplatin plus etoposide), and radiation to the chest. The goal is to see how many tumors shrink or disappear. The study will enroll 27 people and follow them for up to 2 years on maintenance therapy. Because it is a small, single-arm study without a comparison group, results will be preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- benmelstobart (immunotherapy), anlotinib (anti-angiogenic drug), cisplatin or carboplatin (chemotherapy), etoposide (chemotherapy), and thoracic radiation
- What this could lead to
- If successful, this combination could improve tumor shrinkage and delay progression in limited-stage small cell lung cancer, potentially offering a more effective first-line treatment option.
- What could go wrong
- This is a small, early-phase (2) single-arm study with only 27 participants, so results may not be generalizable. Combining multiple therapies increases the risk of serious side effects, and the trial has not yet started recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.